Tanton Clare, Mesher David, Beddows Simon, Soldan Kate, Clifton Soazig, Panwar Kavita, Field Nigel, Mercer Catherine H, Johnson Anne M, Sonnenberg Pam
Research Department of Infection & Population Health, University College London, Mortimer Market Centre, London WC1E 6JB, UK.
Centre for Infectious Disease Surveillance and Control (CIDSC), Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK.
Papillomavirus Res. 2017 Jun;3:36-41. doi: 10.1016/j.pvr.2017.01.001.
In 2008, the UK introduced an HPV immunisation programme in girls. Population-based prevalence estimates of bivalent (HPV-16/18), quadrivalent (HPV-6/11/16/18) and 9-valent (HPV-6/11/16/18/31/33/45/52/58) vaccine types, and comparison over time, are needed to monitor impact, evaluate effectiveness and guide decision-making on vaccination strategies.
The third National Survey of Sexual Attitudes and Lifestyles (Natsal-3) in 2010-12, tested urine for HPV from 2569 sexually-experienced women aged 16-44. We report type-specific HPV prevalence and compare results with 1798 women in Natsal-2 (1999-2001) using age-adjusted prevalence ratios (APR).
In Natsal-3, 4.2% of women aged 16-44y were positive for HPV-16/18 and 2.9% for HPV-6/11. In 16-20 year olds, 4.5%, 10.8% and 20.7% had at least one bivalent, quadrivalent or 9-valent vaccine type, respectively. Three-dose vaccine coverage was 52.0% in women aged 18-20y. In this age group, HPV-16/18 prevalence was lower in Natsal-3 than Natsal-2 (5.8% vs 11.2%; APR=0.48[95%CI: 0.24-0.93]), however, prevalences of HPV-6/11, HPV-31/33/45 and HPV-52/58 were unchanged. HPV-16/18 prevalence was also unchanged in women aged 21-44y (APR=0.85[0.61-1.19]).
These probability surveys provide evidence of the impact of the bivalent immunisation programme. Reductions were specific to HPV-16/18 and to the age group eligible for vaccination. However, substantial vaccine-preventable HPV remains.
2008年，英国在女孩中推行了人乳头瘤病毒（HPV）免疫计划。需要基于人群的二价（HPV - 16/18）、四价（HPV - 6/11/16/18）和九价（HPV - 6/11/16/18/31/33/45/52/58）疫苗类型的流行率估计值，并进行长期比较，以监测影响、评估有效性并指导疫苗接种策略的决策。
2010 - 2012年的第三次全国性态度和生活方式调查（Natsal - 3），对2569名16 - 44岁有性经历的女性的尿液进行了HPV检测。我们报告了特定类型的HPV流行率，并使用年龄调整患病率比（APR）将结果与Natsal - 2（1999 - 2001年）中的1798名女性进行了比较。
在Natsal - 3中，16 - 44岁女性中4.2%的人HPV - 16/18呈阳性，2.9%的人HPV - 6/11呈阳性。在16 - 20岁的人群中，分别有4.5%、10.8%和20.7%的人至少感染一种二价、四价或九价疫苗所针对的HPV类型。18 - 20岁女性的三剂疫苗接种覆盖率为52.0%。在这个年龄组中，Natsal - 3中HPV - 16/18的流行率低于Natsal - 2（5.8%对11.2%；APR = 0.48[95%CI：0.24 - 0.93]），然而，HPV - 6/11、HPV - 31/33/45和HPV - 52/58的流行率没有变化。21 - 44岁女性中HPV - 16/18的流行率也没有变化（APR = 0.85[0.61 - 1.19]）。
这些概率调查提供了二价免疫计划影响的证据。下降仅针对HPV - 16/18以及符合接种条件的年龄组。然而，大量可通过疫苗预防的HPV仍然存在。
